This underlies the current standard of care use of anti‐VEGF therapies such as Lucentis (ranibizumab), Eylea (aflibercept), Beovu (brolucizumab), and Avastin (bevacizumab) that revolutionized the clinical management of vascular and exudative diseases of the retina (e.g. macular edema, retinopathy of prematurity, age‐related macular degeneration, diabetic retinopathy, retinal vein occlusion, and myopic choroidal neovascularization). The gene discussed is VEGFA; the disease is diabetic retinopathy.